UB Paderborn / Katalog / Suche / in CDI

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3744-3752

2014

Link zum Volltext

Verfügbarkeit prüfen

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3366-3373

2011

Link zum Volltext

Verfügbarkeit prüfen

Systemic Therapy for HER2-Positive Early-Stage Breast Cancer

Current problems in cancer, 2016-03, Vol.40 (2-4), p.106-116

2016

Link zum Volltext

Verfügbarkeit prüfen

ERBB2 (HER2) Testing in Breast Cancer

JAMA : the journal of the American Medical Association, 2016-03, Vol.315 (12), p.1280

2016

Link zum Volltext

Verfügbarkeit prüfen

Influence of depression on breast cancer treatment and survival: A Kentucky population‐based study

Cancer, 2023-06, Vol.129 (12), p.1821-1835

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3942-3948

2017

Link zum Volltext

Verfügbarkeit prüfen

Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

JNCI : Journal of the National Cancer Institute, 2013-12, Vol.105 (23), p.1782-1788

2013

Link zum Volltext

Verfügbarkeit prüfen

Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.djv304

2016

Link zum Volltext

Verfügbarkeit prüfen

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

Cancer epidemiology, biomarkers & prevention, 2016-01, Vol.25 (1), p.51-59

2016

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution

Clinical breast cancer, 2019-08, Vol.19 (4), p.e495-e500

2019

Link zum Volltext

Verfügbarkeit prüfen

Reply to V. Pitini et al

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2225-2225

2013

Link zum Volltext

Verfügbarkeit prüfen

Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23

Journal of clinical oncology, 2001-02, Vol.19 (4), p.931-942

2001

Link zum Volltext

Verfügbarkeit prüfen

Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?

Pathology Research International, 2010-10, Vol.2011, p.825627-4

2010

Link zum Volltext

Verfügbarkeit prüfen

Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12044-e12044

2019

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1673-1684

2005

Link zum Volltext

Verfügbarkeit prüfen

Advances in adjuvant therapy for breast cancer

Clinical advances in hematology & oncology, 2006-03, Vol.4 (3 Suppl 7), p.suppl 1, 4

2006

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of postoperative Adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum : National Surgical Adjuvant breast and Bowel Project Protocol R-02

JNCI : Journal of the National Cancer Institute, 2000-03, Vol.92 (5), p.388-396

2000

Link zum Volltext

Verfügbarkeit prüfen

Neglected breast cancer in the Appalachians

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13023-e13023

2018

Link zum Volltext

Verfügbarkeit prüfen

Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.1

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.532-532

2015

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.530-530

2015

Link zum Volltext

Verfügbarkeit prüfen

Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18018-e18018

2016

Link zum Volltext

Verfügbarkeit prüfen

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

Journal of clinical oncology, 1997-05, Vol.15 (5), p.1858-1869

1997

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2837-2837

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Systemic Therapy for HER2-Positive Early-Stage Breast Cancer

ERBB2 (HER2) Testing in Breast Cancer

Influence of depression on breast cancer treatment and survival: A Kentucky population‐based study

Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution

Reply to V. Pitini et al

Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23

Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?

Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Advances in adjuvant therapy for breast cancer

Randomized trial of postoperative Adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum : National Surgical Adjuvant breast and Bowel Project Protocol R-02

Neglected breast cancer in the Appalachians

Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy

Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer

Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway

Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT)

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

Suchergebnisse filtern